Form 4: Acrivon CEO Plans Future Share Sale for Tax
Insider Transaction Report
Acrivon Therapeutics' President and CEO, Peter Blume-Jensen, reported a planned future disposition of 19,904 common shares on November 21, 2025, to cover tax obligations from restricted stock unit vesting under a Rule 10b5-1 plan.
Summary
- Peter Blume-Jensen, President and CEO, and a Director of Acrivon Therapeutics, Inc., reported a planned disposition of common stock.
- The transaction, involving 19,904 shares of common stock, is scheduled for November 21, 2025, at a price of $2.3 per share.
- This disposition is intended to satisfy mandatory tax withholding requirements upon the future vesting of restricted stock units, executed pursuant to a Rule 10b5-1 plan.
- Following this planned transaction, Peter Blume-Jensen is expected to directly beneficially own 2,046,771 shares of common stock.
- Kristina Masson, EVP Business Operations and a Director, who is Peter Blume-Jensen's spouse, will indirectly beneficially own 2,046,771 shares through Peter's holdings, disclaiming ownership except for pecuniary interest.
- Peter Blume-Jensen will indirectly beneficially own 314,706 shares through Kristina Masson's holdings, disclaiming ownership except for pecuniary interest.
Sentiment
Score: 5
Explanation: A Form 4 reporting a planned future tax withholding on RSU vesting under a 10b5-1 plan is a neutral event. It reflects a standard compensation practice and does not indicate a positive or negative sentiment about the company's performance or future prospects.
Future Outlook
NA
Industry Context
NA
Related Party Transactions
- The filing notes that Peter Blume-Jensen and Kristina Masson are spouses, and each disclaims beneficial ownership of the other's direct holdings except to the extent of their pecuniary interest. This clarifies the indirect ownership reported.
Stakeholder Impact
- Shareholders: The filing reports a pre-arranged, non-discretionary sale by an insider to cover future tax obligations from RSU vesting, executed under a Rule 10b5-1 plan. This is a routine compensation event and generally does not signal a change in management's confidence or the company's prospects. It represents a minor, planned dilution.
Key Dates
| Date | Description |
|---|---|
| 11/21/2025 | Planned date of transaction (vesting of restricted stock units and subsequent tax withholding) under a Rule 10b5-1 plan. |
| 11/25/2025 | Date the Form 4 was signed and filed, reporting the future planned transaction. |
Recommendation
holdThe filing is a routine Form 4 for a planned future tax withholding related to restricted stock unit vesting under a 10b5-1 plan. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Investors should 'hold' and await more substantive corporate updates.
Keywords
Acrivon Therapeutics, ACRV, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, 10b5-1 plan, Peter Blume-Jensen, Kristina Masson, CEO, EVP
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.